Behavioral Neuroscience Laboratory, University of Nevada, Las Vegas, NV, USA.
Neurobiol Dis. 2013 Aug;56:116-30. doi: 10.1016/j.nbd.2013.04.010. Epub 2013 Apr 28.
Alzheimer's disease (AD) represents an escalating global threat as life expectancy and disease prevalence continue to increase. There is a considerable need for earlier diagnoses to improve clinical outcomes. Fluid biomarkers measured from cerebrospinal fluid (CSF) and blood, or imaging biomarkers have considerable potential to assist in the diagnosis and management of AD. An additional important utility of biomarkers is in novel therapeutic development and clinical trials to assess efficacy and side effects of therapeutic interventions. Because many biomarkers are initially examined in animal models, the extent to which markers translate from animals to humans is an important issue. The current review highlights many existing and pipeline biomarker approaches, focusing on the degree of correspondence between AD patients and animal models. The review also highlights the need for greater translational correspondence between human and animal biomarkers.
阿尔茨海默病（AD）是一种不断加剧的全球性威胁，因为预期寿命和疾病流行率不断增加。为了改善临床结果，非常需要更早的诊断。从脑脊液（CSF）和血液中测量的液体生物标志物或成像生物标志物具有很大的潜力来辅助 AD 的诊断和管理。生物标志物的另一个重要用途是在新的治疗方法的开发和临床试验中，评估治疗干预的疗效和副作用。因为许多生物标志物最初是在动物模型中进行检查的，所以标记物从动物到人类的转化程度是一个重要问题。本综述重点介绍了许多现有的和潜在的生物标志物方法，重点关注 AD 患者和动物模型之间的对应程度。该综述还强调了在人类和动物生物标志物之间需要更大的转化对应。
